AR078952A1 - Formulaciones de comprimidos revestidos - Google Patents

Formulaciones de comprimidos revestidos

Info

Publication number
AR078952A1
AR078952A1 ARP100104156A ARP100104156A AR078952A1 AR 078952 A1 AR078952 A1 AR 078952A1 AR P100104156 A ARP100104156 A AR P100104156A AR P100104156 A ARP100104156 A AR P100104156A AR 078952 A1 AR078952 A1 AR 078952A1
Authority
AR
Argentina
Prior art keywords
percent
weight
composition according
disintegrants
granulation
Prior art date
Application number
ARP100104156A
Other languages
English (en)
Inventor
Chimanlall Goolcharran
Mainuddin Mahmud
Muhammad Ashraf
Arwinder Singh Nagi
Krishnendu Ghosh
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078952(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR078952A1 publication Critical patent/AR078952A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona formulaciones de comprimidos revestidos que comprenden maleato de neratinib, y procedimientos mejorados para fabricar dichos comprimidos revestidos. Reivindicacion 1: Una composicion farmacéuticamente aceptable caracterizada porque comprende: una granulacion que comprende los componentes intragranulares: (a) un 10-70 por ciento en peso de maleato de neratinib; (b) un 15-65 por ciento en peso de una o más cargas; (c) un 0-8 por ciento en peso de uno o más disgregantes: y (d) un 0,2-8 por ciento en peso de uno o más deslizantes; y (e) un 5-15 por ciento en peso de uno o más agentes modificadores de superficie, en la que la granulacion está combinada con componentes extragranulares, (f) un 1-25 por ciento en peso de una o más cargas; (g) un 0-8 por ciento en peso de uno o más disgregantes y (h) un 01-3 por ciento en peso de uno o más lubricantes. Reivindicacion 8: La composicion de acuerdo con la reivindicacion 4, caracterizada porque la cantidad de manitol y celulosa microcristalina, como componente intragranular, es de aproximadamente un 50 por ciento en peso. Reivindicacion 11: La composicion de acuerdo con la reivindicacion 4, caracterizada porque es en forma de una dosificacion oral de 40 mg, 80 mg o 240 mg. Reivindicacion 15: El procedimiento de acuerdo con la reivindicacion 13 o 14, caracterizado porque el agente modificador de superficie es povidona. Reivindicacion 16: Un procedimiento para tratar cáncer caracterizado porque comprende administrar una cantidad eficaz de una composicion de acuerdo con la reivindicacion 1.
ARP100104156A 2009-11-09 2010-11-09 Formulaciones de comprimidos revestidos AR078952A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25940309P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
AR078952A1 true AR078952A1 (es) 2011-12-14

Family

ID=43478191

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100104156A AR078952A1 (es) 2009-11-09 2010-11-09 Formulaciones de comprimidos revestidos
ARP180103329A AR114143A2 (es) 2009-11-09 2018-11-14 Formulaciones de comprimidos revestidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180103329A AR114143A2 (es) 2009-11-09 2018-11-14 Formulaciones de comprimidos revestidos

Country Status (21)

Country Link
US (2) US8518446B2 (es)
EP (3) EP4066821A1 (es)
JP (3) JP5835883B2 (es)
CN (2) CN103893140B (es)
AR (2) AR078952A1 (es)
AU (1) AU2010316683B2 (es)
CA (1) CA2780428C (es)
CY (1) CY1122330T1 (es)
DK (1) DK2498756T4 (es)
ES (1) ES2757882T5 (es)
FI (1) FI2498756T4 (es)
HR (1) HRP20192026T4 (es)
HU (1) HUE046606T2 (es)
LT (1) LT2498756T (es)
NZ (1) NZ599763A (es)
PL (1) PL2498756T5 (es)
PT (1) PT2498756T (es)
RS (1) RS59599B2 (es)
SI (1) SI2498756T2 (es)
TW (1) TWI466690B (es)
WO (1) WO2011055303A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CA2596714C (en) 2005-02-03 2014-06-17 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9439897B2 (en) 2007-11-06 2016-09-13 Immunolight, Llc Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
ES2431355T3 (es) 2008-06-17 2013-11-26 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
ES2968373T3 (es) 2008-08-04 2024-05-09 Wyeth Llc Combinaciones antineoplásicas de neratinib y capecitabina
EP4218760A3 (en) 2009-04-06 2023-08-16 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
SI2498756T2 (sl) * 2009-11-09 2023-04-28 Wyeth Llc Tabletne formulacije neratinib maleata
AU2010315362B2 (en) * 2009-11-09 2015-01-22 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
LT3141542T (lt) 2011-12-28 2020-09-25 Global Blood Therapeutics, Inc. Pakeistieji benzaldehido junginiai ir jų panaudojimas didinant audinių aprūpinimą deguonimi
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
SG11201507349TA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9818967B2 (en) * 2013-06-28 2017-11-14 Universal Display Corporation Barrier covered microlens films
CN104337782A (zh) * 2013-08-02 2015-02-11 山东新时代药业有限公司 一种甲磺酸伊马替尼片剂
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG10201804139VA (en) 2014-02-07 2018-06-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2015123699A1 (en) 2014-02-17 2015-08-20 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
US10085993B2 (en) * 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
KR102305932B1 (ko) * 2015-06-29 2021-09-28 플로로놀 인코퍼레이티드 갈조류의 고체 약제학적 조성물
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
CN106831710A (zh) * 2015-12-07 2017-06-13 常州爱诺新睿医药技术有限公司 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
BR112019004356A2 (pt) * 2016-09-07 2019-05-28 Agios Pharmaceuticals Inc composições de comprimido
TWI778983B (zh) * 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018201131A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
KR20200078561A (ko) * 2017-10-24 2020-07-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 퀴놀린 유도체를 함유하는 약학 조성물
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
US20220378788A1 (en) * 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
EP4142699A1 (en) * 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
WO2023172958A1 (en) * 2022-03-08 2023-09-14 Onkosxcel Therapeutics, Llc Stable formulations of talabostat

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
AR046544A1 (es) * 2003-10-15 2005-12-14 Wyeth Corp Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
JP2008515984A (ja) * 2004-10-13 2008-05-15 ワイス Ｐｉ３ｋ阻害剤としての１７−ヒドロキシワートマニンの類似体
WO2006085168A2 (en) 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
WO2006116514A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget, compositions, and methods of preparing the same
CA2629249C (en) * 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
JP2007169273A (ja) * 2005-11-28 2007-07-05 Takeda Chem Ind Ltd 杵付着を改善した医薬製剤
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
WO2008089087A2 (en) * 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
JP5284967B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 打錠障害を生じない錠剤製剤
JP2009089982A (ja) * 2007-10-11 2009-04-30 Ohara Yakuhin Kogyo Kk 打錠用造粒物の造粒方法
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2011002857A2 (en) * 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
SI2498756T2 (sl) * 2009-11-09 2023-04-28 Wyeth Llc Tabletne formulacije neratinib maleata

Also Published As

Publication number Publication date
JP2017075192A (ja) 2017-04-20
HRP20192026T4 (hr) 2023-03-31
ES2757882T3 (es) 2020-04-30
TW201138774A (en) 2011-11-16
US20110111018A1 (en) 2011-05-12
NZ599763A (en) 2014-06-27
HRP20192026T1 (hr) 2020-02-07
CA2780428C (en) 2018-02-13
EP2498756A1 (en) 2012-09-19
CN102724970B (zh) 2014-06-25
PT2498756T (pt) 2019-11-26
US8790708B2 (en) 2014-07-29
EP4066821A1 (en) 2022-10-05
JP2015091882A (ja) 2015-05-14
ES2757882T5 (es) 2023-05-10
WO2011055303A1 (en) 2011-05-12
DK2498756T3 (da) 2019-11-25
CN103893140B (zh) 2016-06-01
JP5835883B2 (ja) 2015-12-24
CY1122330T1 (el) 2021-01-27
US8518446B2 (en) 2013-08-27
DK2498756T4 (da) 2023-03-20
RS59599B1 (sr) 2020-01-31
AU2010316683A1 (en) 2012-05-24
LT2498756T (lt) 2019-12-10
EP3566697A1 (en) 2019-11-13
US20140004184A1 (en) 2014-01-02
HUE046606T2 (hu) 2020-03-30
FI2498756T4 (fi) 2023-03-22
SI2498756T2 (sl) 2023-04-28
AR114143A2 (es) 2020-07-29
AU2010316683B2 (en) 2015-10-08
RS59599B2 (sr) 2023-03-31
EP2498756B1 (en) 2019-09-04
SI2498756T1 (sl) 2020-01-31
CN102724970A (zh) 2012-10-10
EP2498756B2 (en) 2023-02-15
PL2498756T5 (pl) 2023-04-17
CA2780428A1 (en) 2011-05-12
PL2498756T3 (pl) 2020-03-31
CN103893140A (zh) 2014-07-02
TWI466690B (zh) 2015-01-01
JP2011098964A (ja) 2011-05-19

Similar Documents

Publication Publication Date Title
AR078952A1 (es) Formulaciones de comprimidos revestidos
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
BR112012023021A2 (pt) compostos de indazol e seus usos
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
PE20142101A1 (es) Composiciones farmaceuticas de aliskiren
PE20142440A1 (es) Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
AR077464A1 (es) Terapia de combinacion para el tratamiento de la diabetes
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
PH12014501629A1 (en) Treatment of cognitive disorders with (r)-7- chloro -n- (quinuclidin -3-yl) benzo[b] thiophene -2- carboxamide and pharmaceutically acceptable salts thereof
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
UA116334C2 (uk) Тверді форми дозування бендамустину
JP2013508289A5 (es)
CO6612185A2 (es) Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
AR078951A1 (es) Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos

Legal Events

Date Code Title Description
FC Refusal